

APPLICATION NO.

10/788,920

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCY United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

ATTORNEY DOCKET NO. CONFIRMATION NO.
4020.000283 7396

EXAMINER

45045 7590 10/18/2006

FILING DATE

02/27/2004

RAJINDRA ANEJA NUTRIMED BIOTECH 322 SUNNYVIEW LANE ITHACA, NY 14850

ART UNIT PAPER NUMBER

KISHORE, GOLLAMUDI S

1615

DATE MAILED: 10/18/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

FIRST NAMED INVENTOR

Rajindra Aneja

·	Application No.	Applicant(s)
Office Action Summary	10/788,920	ANEJA, RAJINDRA
	Examiner	Art Unit
	Gollamudi S. Kishore, Ph.D	1615
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).		
Status		
1) Responsive to communication(s) filed on		
	-· action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is		
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.		
closed in description with the produce under Ex parts addyre, 1000 C.B. 11, 400 C.G. 210.		
Disposition of Claims		
4)⊠ Claim(s) <u>53-63 and 66-97</u> is/are pending in the application.		
4a) Of the above claim(s) is/are withdrawn from consideration.		
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) <u>53-63 and 66-97</u> are subject to restriction and/or election requirement.		
Application Papers		
9)☐ The specification is objected to by the Examiner.		
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).		
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.		
Priority under 35 U.S.C. § 119		
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 		
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application Paper No(s)/Mail Date		

Application/Control Number: 10/788,920 Page 2

Art Unit: 1615

DETAILED ACTION

Applicant's letter dated 9-19-06 is acknowledged. In view of the inadvertent inclusion of canceled claims the previous restriction requirement is withdrawn. The following is the new restriction requirement.

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 53-55 and 62 are drawn to liquid crystalline multimolecular aggregates, liposomes or lipid complexes and a kit, classified in class 428, subclass 402.2.
 - II. Claims 56-61, 63, 66-96 are, drawn to a method of making the liposomes or lipid complexes, classified in class 264, subclass 4.1
 - III. Claim 97 is, drawn to a method of encapsulating or entrapping a selected agent in liposomes or lipid complex, classified in class 424, subclass 450.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions II and I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make another and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the product can be formed by admixing and sonicating the amphiphilic molecules without prior prehydration (classical method of preparation of liposomes).

Application/Control Number: 10/788,920 Page 3

Art Unit: 1615

3. Inventions II and III are independent and distinct in that they are two distinct methods one involving no active agent and the other involving the encapsulation of active agent.

- 3. Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.
- 4. Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art due to their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 5. This application contains claims directed to the following patentably distinct species:

Species in Group I:

a) liquid crystalline multimolecular aggregates and a kit containing amphiphilic molecules; b) liposomes and kit containing liposomes.

Species in Group II:

- a) method in claims 56-57, 61, 63, 66-96; b) method in claims 58-60.
- 6. The species are independent or distinct because species in Group I are different products and species in Group II are different methods.

Application/Control Number: 10/788,920

Art Unit: 1615

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, none of the claims is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

Because of the involvement of both groups and species in the election requirements, a telephone call was not made

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gollamudi S. Kishore, Ph.D whose telephone number is (571) 272-0598. The examiner can normally be reached on 6:30 AM- 4 PM, alternate Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Woodward Michael can be reached on (571) 272-8373. The fax phone

Application/Control Number: 10/788,920

Art Unit: 1615

number for the organization where this application or proceeding is assigned is 571-

273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Gollamudi S Kishore, Ph.D

Page 5

Primary Examiner Art Unit 1615

GSK